Skip to main content
. 2023 Feb 5;11(1):29. doi: 10.3390/pharmacy11010029

Table 4.

Subjects’ data with several pharmacogene variants (one risk factor).

N Sex Age Diagnosis Therapy (DD) Adverse Event Pharmacogenetic Results/Phenotype
1 F 72

  • AF

  • AH

  • COPD

  • Hyperlipidemia

  • Hyperuricemia

  • RIVA (20 mg)

  • Bisoprolol (1.25 mg)

  • Eplerenone (25 mg)

  • Furosemide (40 mg)

  • Perindopril butylamine/

  • Indapamide (4/12.5 mg)

 Epistaxis
4 months following the introduction of RIVA		 CYP2J2 *1/*7
decreased enzyme activity
CYP3A5 *1/*3
expresser
ABCB1 (MDR1)
1236-2677-3435-rs4148738
CC-GG-CC-GG
risk allele
ABCG2 421CA
decreased function
2 F 69

  • AF

  • AH

  • Hypothyroidism

  • PAD

  • RIVA (20 mg)

  • Atorvastatin (20 mg)

  • Bisoprolol 1.25 mg)

  • Diazepam (2 mg)

  • Levothyroxine (100 mg)

  • Perindopril/Indapamide/Amlodipine (10/2.5/5 mg)

 Epistaxis
5 months following the introduction of RIVA		 ABCB1 (MDR1)
1236-2677-3435-rs4148738
CT-GT-CT-GA
intermediate
function
3 M 66

  • AF

  • Anaemia sideropenica

  • CAD

  • Colon polyps

  • Post STEMI

  • RIVA (20 mg)

  • Atorvastatin (40 mg)

  • Perindopril/Amlodipine (10/10 mg)

  • Trimetazidine (2 × 35 mg)

  • Nebivolol (5 mg)

  • Moxonidine (0.4 mg)

  • Furosemide (40 mg)

  • Pantoprazole (20 mg)

 Gastrointestinal bleeding and anaemia
4 months following the introduction of RIVA		 CYP3A4 *1/*22
decreased enzyme activity
ABCB1 (MDR1)
1236-2677-3435-rs4148738
CC-GG-CC-GA
risk allele
ABCG2 421AA
poor function

AF atrial fibrillation; AH arterial hypertension; CAD coronary artery disease; COPD Chronic obstructive pulmonary disease; DD daily dose; PAD peripheral artery disease RIVA rivaroxaban; STEMI ST-elevation myocardial infarction.